Guangzhou Fuda Cancer Hospital is a specialized hospital which mainly treats middle and late-stage tumor patients at home and abroad. The hospital adopts the latest international anti-cancer concepts, takes the middle and late-stage malignant tumors, a world medical problem, as the main target of treatment, prolongs the patients' life span and improves the patients' quality of life as the main goal, and takes tumor Percutaneous minimally invasive treatment is the center, and it implements the combination of traditional technology (surgery, radiotherapy and chemotherapy) and high technology, the combination of many kinds of high technology, and the combination of traditional Chinese medicine and western medicine.
A series of high and new technologies such as argon helium knife cold ablation, photodynamic therapy, particle knife therapy (radioactive iodine particle implantation), radiofrequency thermal ablation, vascular interventional therapy, bio-immunotherapy (DCCTL), local immunotherapy in the tumor bed, anti-angiogenic therapy, tumor suppressor gene therapy, and percutaneous chemical ablation therapy have been carried out. We focus on the "3C" treatment model led by cryoablation (CSA), microvascular intervention therapy (CMI) and combined immunotherapy (CIC), which has created a number of industry firsts. Among them, more than 6,000 cases of tumors have been treated by cryoablation, which is the highest number of cases in the world.
He has accumulated rich clinical and scientific research experience in the comprehensive treatment of liver cancer, lung cancer, glioma, breast cancer, gastric cancer, esophageal cancer, intestinal cancer, nasopharyngeal cancer, skin cancer, bone tumors, head and neck cancer, renal cancer, bladder cancer, ovarian cancer, uterine cancer, lymphoma and other tumors.
He edited and published the world's first monograph on cryotherapy "Tumor Cryotherapy"; he won the first gold medal awarded to Chinese by the International Congress of Cryonics in Japan for the successful cryotherapy of pancreatic cancer. on November 2, 2011, at the 16th International Congress of Cryonics in Vienna, Austria, the book edited by Xu Kecheng and Niu Lizhi won the The book edited by Xu Kecheng and Niu Lizhi won the "Outstanding Book Award", and Chen Jibing won the "Outstanding Lecture Award"; after public voting, Xu Kecheng and Niu Lizhi were elected as the executive members of the International Society of Cryotherapy (ISC), and Xu Kecheng was elected as the President of the ISC and received the Grand Gold Medal conferred by the General Assembly. awarded the Grand Gold Medal.